The anti-ErbB2 antibody H2-18 and the pan-PI3K inhibitor GDC-0941 effectively inhibit trastuzumab-resistant ErbB2-overexpressing breast cancer

Trastuzumab, an anti-ErbB2 humanized antibody, brings benefit to patients with ErbB2-amplified metastatic breast cancers. However, the resistance to trastuzumab is common. Our previously reported H2-18, an anti-ErbB2 antibody, potently induced programmed cell death in trastuzumab-resistant breast ca...

Descripción completa

Detalles Bibliográficos
Autores principales: Wang, Lingfei, Yu, Xiaojie, Wang, Chao, Pan, Shujun, Liang, Beibei, Zhang, Yajun, Chong, Xiaodan, Meng, Yanchun, Dong, Jian, Zhao, Yirong, Yang, Yang, Wang, Huajing, Gao, Jie, Wei, Huafeng, Zhao, Jian, Wang, Hao, Hu, Chaohua, Xiao, Wenze, Li, Bohua
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Impact Journals LLC 2017
Materias:
Research Paper
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5581078/
https://www.ncbi.nlm.nih.gov/pubmed/28881779
http://dx.doi.org/10.18632/oncotarget.17907

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5581078/
https://www.ncbi.nlm.nih.gov/pubmed/28881779
http://dx.doi.org/10.18632/oncotarget.17907

Ejemplares similares